Literature DB >> 36208384

Early GLS changes detection after chemoradiation in locally advanced non-small cell lung cancer (NSCLC).

Simona Mega1, Michele Fiore2, Myriam Carpenito3, Maria Laura Novembre1, Marianna Miele2, Luca Eolo Trodella2, Francesco Grigioni1, Edy Ippolito2, Sara Ramella2.   

Abstract

PURPOSE: Chemoradiation is the standard treatment in patients with locally advanced non-small-cell lung cancer (LA-NSCLC), and thanks to the recent combination with immunotherapy, median survival has unexpectedly improved. This study aims to evaluate early changes in cardiac function after chemoradiotherapy (CRT) in LA-NSCLC by multimodal use of advanced imaging techniques.
MATERIALS AND METHODS: This is a prospective, observational cohort study. At the beginning of combined treatment, screening tests including blood samples, electrocardiogram (ECG), echocardiographic examination (TTE), and cardiac magnetic resonance were performed in all patients with LA-NSCLC. ECG and cardiac marker assays were performed weekly during treatment. ECG and TTE were performed at month 1 (M1) and month 3 (M3) after the end of CRT.
RESULTS: This preliminary analysis included thirty-four patients with a mean age of 69.5 years. The median follow-up was 27.8 months. 62% of patients were in stage IIIA. Radiation therapy was delivered with a median total dose of 60 Gy with conventional fractionation. All patients were treated with concurrent CRT, and 65% of cases were platinum-based therapy. Global longitudinal strain (GLS) and ejection fraction (EF) progressively decreased from baseline to M1 and M3. There was a strong correlation between GLS and EF reduction (at M1: p = 0.034; at M3: p = 0.018). Cardiac arrhythmias occurred in eight patients (23.5%) at a mean follow-up of 15.8 months after CRT.
CONCLUSIONS: Reduction in GLS is an early sign occurring after the end of CRT for LA-NSCLC. Future studies are needed to identify variables that can increase the risk of cardiac events in this patient population to implement adequate damage prevention strategies.
© 2022. Italian Society of Medical Radiology.

Entities:  

Keywords:  Chemoradiation; Global longitudinal strain; NSCLC; Radiation therapy

Year:  2022        PMID: 36208384     DOI: 10.1007/s11547-022-01557-7

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   6.313


  28 in total

1.  Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.

Authors:  Patrizio Lancellotti; Vuyisile T Nkomo; Luigi P Badano; Jutta Bergler-Klein; Jutta Bergler; Jan Bogaert; Laurent Davin; Bernard Cosyns; Philippe Coucke; Raluca Dulgheru; Thor Edvardsen; Oliver Gaemperli; Maurizio Galderisi; Brian Griffin; Paul A Heidenreich; Koen Nieman; Juan C Plana; Steven C Port; Marielle Scherrer-Crosbie; Ronald G Schwartz; Igal A Sebag; Jens-Uwe Voigt; Samuel Wann; Phillip C Yang
Journal:  J Am Soc Echocardiogr       Date:  2013-09       Impact factor: 5.251

2.  Incidence and trends of cardiovascular mortality after common cancers in young adults: Analysis of surveillance, epidemiology and end-results program.

Authors:  Sadeer G Al-Kindi; Guilherme H Oliveira
Journal:  World J Cardiol       Date:  2016-06-26

3.  European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies.

Authors:  Arturo Evangelista; Frank Flachskampf; Patrizio Lancellotti; Luigi Badano; Rio Aguilar; Mark Monaghan; José Zamorano; Petros Nihoyannopoulos
Journal:  Eur J Echocardiogr       Date:  2008-07

4.  The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy.

Authors:  Lu Chen; Jingjuan Huang; Weihua Wu; Shengjun Ta; Xiaoyi Xie
Journal:  Int J Cardiovasc Imaging       Date:  2019-04-02       Impact factor: 2.357

5.  Radiotherapy-induced global and regional differences in early-stage left-sided versus right-sided breast cancer patients: speckle tracking echocardiography study.

Authors:  Suvi Sirkku Tuohinen; Tanja Skyttä; Tuija Poutanen; Heini Huhtala; Vesa Virtanen; Pirkko-Liisa Kellokumpu-Lehtinen; Pekka Raatikainen
Journal:  Int J Cardiovasc Imaging       Date:  2016-11-21       Impact factor: 2.357

Review 6.  QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.

Authors:  Katharina Wenzel-Seifert; Markus Wittmann; Ekkehard Haen
Journal:  Dtsch Arztebl Int       Date:  2011-10-14       Impact factor: 5.594

7.  Prognostic and Added Value of Echocardiographic Strain for Prediction of Adverse Outcomes in Patients with Locally Advanced Non-Small Cell Lung Cancer after Radiotherapy.

Authors:  Lu Chen; Shengjun Ta; Weihua Wu; Changlu Wang; Qin Zhang
Journal:  Ultrasound Med Biol       Date:  2018-10-23       Impact factor: 2.998

Review 8.  Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.

Authors:  Akshay Gupta; Andrew T Lawrence; Kousik Krishnan; Clifford J Kavinsky; Richard G Trohman
Journal:  Am Heart J       Date:  2007-06       Impact factor: 4.749

9.  Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.

Authors:  Jhanelle E Gray; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki Hyeong Lee; Byoung Chul Cho; David Planchard; Luis Paz-Ares; Corinne Faivre-Finn; Johan F Vansteenkiste; David R Spigel; Catherine Wadsworth; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu; Scott J Antonia
Journal:  J Thorac Oncol       Date:  2019-10-14       Impact factor: 15.609

10.  Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study.

Authors:  Juliette Degens; D De Ruysscher; Ruud Houben; Bastiaan Kietselaer; Gerben Bootsma; Lizza Hendriks; Ellen Huijbers; Annemie Schols; Anne-Marie C Dingemans
Journal:  BMJ Open       Date:  2020-09-28       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.